RECRUITING

Thermogenic Silencer Regulatory Factors in Humans

Talk to us

Conditions

ObesityMetabolic DiseaseCold Exposure

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A promising approach to correct the metabolic dysfunction associated with obesity is to activate brown fat non-shivering thermogenesis (NST). A critical limitation with NST as a therapeutic option, however, is that this beneficial process is silenced under human physiological temperature conditions and the mechanisms of how this occurs is unknown. This study will be the first to identify human NST silencing factors that may be targeted for the treatment of obesity and metabolic disorders.

Official Title

Identification of Thermogenic Silencing Regulatory Factors as Biomarkers of Metabolic Health in Humans

Quick Facts

Study Start:2024-08-16
Study Completion:2027-05
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06424132

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age between 18 years old and 35
  2. 2. Lean group: BMI is between 18.5 and 24.9. HgA1c \<5.7%
  3. 3. Obese group: BMI is \>30, HgA1c \<5.7%
  4. 4. Obese group with Type II diabetes: BMI is \>30, HgA1c is \>6.5% If on oral medication for diabetes management, HgA1c may be \< 6.5% The following medications are also acceptable: statins, aspirin, angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARB).
  1. 1. Diabetes type I (self-report)
  2. 2. Diagnosis of thyroid disease (including goiter, hyperthyroidism, hypothyroidism, thyroiditis)(self-report)
  3. 3. Diagnosis with cancer including skin cancer (self-report)
  4. 4. Diagnosis or evidence of Raynaud's Syndrome or systemic sclerosis (self-report)
  5. 5. A recent diagnosis of Coronavirus Disease 2019 (COVID-19) (last 2 weeks) or hospitalized at the time of diagnosis with COVID-19
  6. 6. Any vaccine administration within two weeks preceding the study procedure
  7. 7. Currently pregnant
  8. 8. Currently taking any prescribed medication other than oral contraceptives. Treatments for weight loss or any other supplements that may alter weight or metabolism are not acceptable. Vitamins are acceptable.
  9. 9. Has consumed nicotine (smoking, inhaling, ingesting) within the last 6 months
  10. 10. Has used illicit drugs within the last 6 months (marijuana users are eligible unless consumed in the last 30 days).
  11. 11. Any medical, psychological, or social condition that, in opinion of principle investigators, would jeopardize the health or well-being of the participant during the study procedure or the integrity of the data
  12. 12. Diabetes Type II that is managed by insulin.
  13. 13. Steroid use in the last 30 days to the exclusions

Contacts and Locations

Study Contact

Joeva Barrow, Ph.D., R.D.
CONTACT
607-255-9429
jb2254@cornell.edu
Paul Cohen, Ph.D., M.D.
CONTACT
212-327-7918
pcohen@rockefeller.edu

Principal Investigator

Joeva Barrow, Ph.D., R.D.
PRINCIPAL_INVESTIGATOR
The Rockefeller University and Cornell University
Paul Cohen, Ph.D., M.D.
PRINCIPAL_INVESTIGATOR
The Rockefeller University

Study Locations (Sites)

Rockefeller University
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Rockefeller University

  • Joeva Barrow, Ph.D., R.D., PRINCIPAL_INVESTIGATOR, The Rockefeller University and Cornell University
  • Paul Cohen, Ph.D., M.D., PRINCIPAL_INVESTIGATOR, The Rockefeller University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-16
Study Completion Date2027-05

Study Record Updates

Study Start Date2024-08-16
Study Completion Date2027-05

Terms related to this study

Additional Relevant MeSH Terms

  • Obesity
  • Metabolic Disease
  • Cold Exposure